drugset / Trial / NCT04939467
Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers
Non-randomizedSequentialOpen-labelOther
Summary
A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone when Administered Concurrently in Healthy Volunteers
Timeline
- Start
- 2021-10-15
- Primary completion
- 2021-12-16
- Completion
- 2022-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cudetaxestat | Small molecule | 750 mg | Oral |
| Subject | Nintedanib | Small molecule | 150 mg | Oral |
| Subject | Pirfenidone | Small molecule | 267 mg | Oral |
Indications
No indication recorded.